/SARCURA and imec to collaborate on high throughput cytometry solution for automated (T-)cell separation, tackling manufacturing challenges of cell and gene therapies.

Press release

SARCURA and imec to collaborate on high throughput cytometry solution for automated (T-)cell separation, tackling manufacturing challenges of cell and gene therapies.

Collaboration between Sarcura and imec aims to develop a silicon photonics-based cytometry solution allowing real-time process control and manipulation of cells.

About imec

Imec is a world-leading research and innovation hub in nanoelectronics and digital technologies. The combination of our widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes us unique. By leveraging our world-class infrastructure and local and global ecosystem of partners across a multitude of industries, we create groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, energy and education.

As a trusted partner for companies, start-ups and universities we bring together more than 4,000 brilliant minds from almost 100 nationalities. Imec is headquartered in Leuven, Belgium and has distributed R&D groups at a number of Flemish universities, in the Netherlands, Taiwan, USA, and offices in China, India and Japan. In 2019, imec's revenue (P&L) totaled 640 million euro.

Further information on imec can be found at www.imec-int.com.

Imec is a registered trademark for the activities of IMEC International (a legal entity set up under Belgian law as a “stichting van openbaar nut”), imec Belgium (IMEC vzw supported by the Government of Flanders), imec the Netherlands (Stichting IMEC Nederland, part of Holst Centre and OnePlanet, supported by the Dutch Government), imec Taiwan (IMEC Taiwan Co.), imec China (IMEC Microelectronics (Shanghai) Co. Ltd.), imec India (Imec India Private Limited) and imec Florida (IMEC USA nanoelectronics design center).

About Sarcura

Sarcura GmbH is an Austrian based early-stage technology company, developing an instrument platform for the GMP manufacturing of autologous cell therapies.  Sarcura was founded in 2019 by an interdisciplinary team of scientific and industry experts. Our platform combines microfluidic processing with silicon chip technology to enable real time process control and manipulation on a cellular level supporting a fully automated manufacturing system. To learn more about Sarcura, please visit: www.sarcura.com